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successfully but only after introducing a multiplicative scale parameter to distin-
guish between both approaches. With 1600 respondents, adding 1 TTO offers more
informative value than adding 1 DC but not as much as adding 2 DC’s.
CONCLUSIONS:The likelihood approach effectively estimates the structure under-
lying the simulated data. Given that DC is less burdensome than TTO, one may
prefer to add more DC’s than TTO’s. That is – as in this case – when the underlying
modelling assumption apply.
UT2
UPDATE OF THE PATIENT-REPORTED OUTCOME AND QUALITY OF LIFE
INSTRUMENTS DATABASE (PROQOLID) USING THE FDA GUIDANCE ON PRO
MEASURES
Caron M, Perrier LL, Vaissier V, Savre I, Acquadro C, Emory MP
MAPI Research Trust, Lyon, France
OBJECTIVES: In 2002, PROQOLID was launched to provide an overview of existing
PRO instruments and facilitate access to the instruments and their developers,
through the structured presentation of synthesized, reliable, and updated data. In
2009, the Food and Drug administration (FDA) published its final guidance on the
use of PRO measures which describes how the FDA will review PRO instruments
used to support claims in approved medical product labeling. The objectives of this
study were to review and adapt the template of PROQOLID to harmonize its struc-
ture and language with those used in the FDA guidance, acknowledging that PRO-
QOLID and the guidance have different OBJECTIVES: provision of information vs.
review of information.METHODS:Content and structure of PROQOLID and the FDA
guidance were compared. Proposed changes in terminology and structure were
submitted to a panel of PRO experts (n2). RESULTS: The information on PRO-
QOLID is divided into 12 sections. The FDA guidance categorizes information into 5
parts. Twelve changes in terminology were made across all sections. For instance,
Time recall” was changed to “Recall/Observation period”, and “Dimensions” to “Do-
mains”. Fourteen changes of structure were made, mainly in Sections 6 and 7. Section
6 (Methodology of development) was renamed “Content Validity documentation”. In
this section, the heading “Information retrieval” was replaced by “Concept elicitation
and Item generation”. “Conceptual framework” will be moved to Section 5 (Descriptive
information). Section 7 (Psychometric properties) was renamed “Measurement Prop-
erties”. Within the “Reliability” heading, a subheading on “Inter-interviewer reproduc-
ibility” was added. A new section was created: “Data analysis and Interpretation. Five
sections remained unchanged (1 to 4, and 8). CONCLUSIONS: The comparison of
PROQOLID and the FDA guidance led to numerous changes in the wording and
structure of the database. These changes will improve the functionality of PRO-
QOLID and help users to better fulfill FDA requirements.
UT3
THE VALIDITY OF THE EQ-5D, SF-6D, SF-36 AND SF-12 IN MENTAL HEALTH
CONDITIONS: A SYSTEMATIC REVIEW
Papaioannou D, Peasgood T, Brazier J, Parry G
University of Sheffield, Sheffield, UK
OBJECTIVES: To assess the validity and responsiveness of the SF-36, SF-12, SF-6D
and EQ-5D in mental health conditions. METHODS: Systematic reviews were un-
dertaken in five mental health conditions. Ten databases were searched to August
2009. Studies were appraised and data extracted. A narrative synthesis was per-
formed on construct validity including known groups validity (KGV) (ability to de-
tect differences in HRQL scores between groups), convergent validity (CV) (strength
of association between generic HRQL and other related measures (e.g. symptoms or
function) and responsiveness (R) (i.e. changes in scores in responders/non-re-
sponders to treatment and correlation with changes in related measures).
RESULTS: Within schizophrenia, the majority of evidence related to the SF-36
(n25) and EQ-5D (n9). Both measures demonstrated KGV but this was mostly
limited to demonstrating differences between individuals with schizophrenia and
the general population. Contradictory results were found in studies measuring CV
and R using clinical measures of symptom severity. For bipolar disorder, 23 studies
were identified, almost exclusively on the SF-36; which was able to detect known
differences in symptom severity and correlated strongly with clinical measures of
depression (weakly with mania measures). For personality disorders; the majority
of studies (6/9) related to the EQ-5D, which showed good KGV and R. For depression
and anxiety, 23 EQ-5D and eight SF-6D studies were identified. Both measures
demonstrated good CV and R for depression; however KGV may be driven by the
presence of co-morbid depression in patients with anxiety disorders.
CONCLUSIONS: Overall, the evidence suggests that the generic HRQL measures are
appropriate in four mental health conditions, but raises doubts about their use in
schizophrenia. Caution is required when interpreting CV evidence using clinical mea-
sures, since the lack of relationship may reflect genuine lack of difference in HRQL. More
evidence using better indicators for testing validity and responsiveness are required.
UT4
COMPARISON OF THE PERFORMANCE OF EQ-5D AND SF-6D IN PATIENTS WITH
CHRONIC PAIN –RESULTS FROM 3 RANDOMIZED CONTROLLED TRIALS
Obradovic M, Lal A, Liedgens H
Grünenthal GmbH, Aachen, Germany
OBJECTIVES: To compare EQ-5D and SF-6D utilities in patients with chronic pain
due to osteoarthritis (OA) of the knee or low back pain (LBP) derived from phase III
trials with tapentadol. METHODS: Three phase III trials with identical design in-
cluded EQ-5D and SF-36 questionnaires to measure quality of life of patients with
pain due to OA or LBP treated with tapentadol prolonged release (PR), oxycodone
controlled release (CR) or placebo. EQ-5D and SF-6D indices were obtained using
the UK weights. The ability of the two utility measurements to discriminate among
different health states was tested. RESULTS: Both SF-6D and EQ-5D utility values
increased from baseline to endpoint (15 weeks). The increase (mean of all patients
with active treatment) was substantially higher when measured with EQ-5D (0.16
vs. 0.06). The EQ-5D better distinguished among health states (different severity of
adverse events, pain relief, withdrawal rates). While utilities were very similar in a
group of patients who tolerated the treatment (0.695 and 0.694 for EQ-5D and SF-6D,
respectively), EQ-5D utilities were considerably lower in patients who withdrew
due to adverse events (0.503 and 0.597 for EQ-5D and SF-6D, respectively). A similar
pattern was seen in patients with various levels of pain relief. In patients with
30% pain relief mean EQ-5D and SF-6D utility was 0.716 and 0.708, respectively.
The EQ-5D utility in patients who withdrew due to lack of efficacy was 0.405, when
analyzing the SF-6D utility this resulted in 0.580. CONCLUSIONS: Both generic
instruments to measure quality of life, EQ-5D and SF-6D, showed that avoidance of
severe treatment-related adverse events and sufficient pain relief has a large ben-
eficial impact on patient’s wellbeing. In the clinical trials analyzed the discrimina-
tive power of the EQ-5D was stronger showing that this instrument is a useful tool
also in pain studies to analyze patient’s QoL.
PODIUM SESSION II:
DISCUSSIONS ON THE ADDED VALUE OF VALUE OF INFORMATION
VI1
DETERMINING THE IMPACT OF MODELING ADDITIONAL SOURCES OF
UNCERTAINTY IN VALUE OF INFORMATION ANALYSIS
Corro Ramos I, Rutten-van mölken MP, Al MJ
Erasmus University, Rotterdam, The Netherlands
The conditional reimbursement policy for expensive medicines in the The Nether-
lands requires real-world data collection on cost-effectiveness within a four years
period (T4) after the initial decision to reimburse a drug (T0). This introduces
new sources of uncertainty, which are less important in an RCT than in real life. This
may affect the priorities for further (real-world) research as determined in a VOI
analysis. OBJECTIVES: Identifying and modeling types of uncertainty that are usu-
ally not parameterized at T0 but may become relevant at T4. Include them in the
VOI analysis.METHODS:We use a hypothetical model with four states and param-
eters related to transition and exacerbation probabilities, costs and utilities. Three
additional uncertainties were parameterized: persistence, compliance and broad-
ening of indication. Persistence refers to the duration of the treatment and it is
determined by the probability of dropping out of the treatment. Compliance is
characterized by the fraction of the treatment benefit obtained due to not taking
the medication as it was indicated. The impact of indication broadening is modeled
as the percentage of the RCT treatment effect realized in the outcome study. These
extra parameters were included in the VOI analysis. RESULTS: Priorities change
when new uncertainties are introduced in the model. Initially, the EVPPI was high-
est for transition probabilities followed by utilities; and it was very low for exacer-
bation probabilities and costs. After new uncertainties are included, compliance
and broadening of indication (which is applied only to the new treatment) become
as relevant as utilities. Persistence however has little impact in the model.
CONCLUSIONS:VOI analysis at T0 should anticipate and parameterize new types
of uncertainty that may emerge during a four year outcomes study. This would
help to focus the real-world outcomes study on those parameters that reduce
uncertainty in the decision to continue the reimbursement most.
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A NOVEL APPROACH TO ANALYSING VALUE DRIVER IMPORTANCE ACROSS
MULTIPLE TARGET PRODUCT PROFILES
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OBJECTIVES: To develop a novel semi-quantitative model to assist pharmaceutical
companies in making investment decisions, by assessing relative importance of
value drivers in a given therapy area and how this translates to perceived value of
a product profile. METHODS: Perceived value for a number of product profiles is
assessed through a semi-quantitative scoring method, followed by an in-depth
qualitative interview. In the scoring phase, respondents rate the relative impor-
tance of value drivers and provide thresholds for minimal and strong value in each
domain. Respondents assess target product profiles, scoring profile performance in
each value driver on a pre-defined scale. RESULTS: This methodology provides a
range of valuable data in understanding the drivers of value in a given therapy area.
First, the relative importance of value drivers can be used to understand which
product attributes (efficacy, safety and tolerability or administration and others)
drive product value. In addition, by providing value thresholds for each driver, we
can understand expectations, in effect defining an ‘ideal’ product scenario. Testing
product profiles against a scale calibrated by these expectations allows us to un-
derstand perceived product value in a set of likely product attributes. In addition,
by testing a number of profiles, trade-offs between different product attributes, and
the effect of these on product value, can be assessed. CONCLUSIONS: The insights
gained from this type of analysis are vital in understanding product development
priorities and the likely pricing and reimbursement potential for future products.
Multiple applications of this technique have confirmed that this is a valuable ap-
proach in supporting pharmaceutical companies to inform their clinical pro-
gramme, pricing and reimbursement strategy or commercial strategy.
VI3
SEQUENTIAL TREATMENT OF FOLLICULAR NON-HODGKIN LYMPHOMA: COST-
EFFECTIVENESS AND VALUE OF INFORMATION
Soini EJ1, Martikainen JA1, Vihervaara V2, Mustonen K2, Nousiainen T3
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OBJECTIVES:To assess the lifetime incremental cost-effectiveness ratios (ICER) per
quality-adjusted life-year (QALY) gained and multinomial expected value of per-
fect information (mEVPI) of sequential follicular lymphoma (FL) treatment in
Finland. METHODS: The novel cancer treatments included rituximab (R) and ben-
damustine (B). A probabilistic Markov-model was developed to simulate patients’
transitions between first-line progression-free (PF1), PF2, progression and death
states using a second-order Monte Carlo-simulation, one month cycle, and half
cycle correction. All patients received the recommended induction with R-cyclo-
phosphamide-doxorubicin-vincristine-prednisone (RCHOP). For the RCHOP-induc-
tion responders, the sequence was continued without the first-line R-maintenance
treatment (RCHOP) or with it (RCHOPR). PF1 was based on the best fitting paramet-
ric extrapolation (Gompertz; 4-year treatment benefit trunk) of PRIMA (Primary
RItuximab and MAintenance) data. After RCHOPR or RCHOP, eligible patients were
assigned to second-line RCOPR/B or RCOPR/COP based on the PRIMA results, B
indication/labelling and the recent ESMO (European Society for Medical Oncology)
guideline for FL. PF2s (5-year treatment benefit trunk) were based on the paramet-
ric estimate of EORTC20981 and adjustment based on Rummel’s trial. After PF2
(progression), patients received best supportive care (BSC). Age-dependent death
was set equal to the larger of EORTC20981 or Finnish background mortality. Payer
costs were included in 2010 value, and the most affordable public drug costs (2/
2011; wastage included) were used. EQ-5D-based utilities were set 0.78 for PF1/PF2
and 0.62 for progression. 3% annual discounting was used. RESULTS: The ICERs for
RCHOPR-RCOPR/B-BSC, RCHOPR-RCOPR/COP-BSC and RCHOP-RCOPR/B-
BSC were €9575, €9881 and €8812 per QALY gained in comparison to RCHOP-
RCOPR/COP-BSC, respectively. According to the cost-effectiveness acceptability
frontier, 47% of patients with RCHOP-RCOPR/COP-BSC, 46% and 68% of patients
with RCHOPR-RCOPR/B-BSC were cost effective at the ICER-levels of €5,000
(mEVPI €5,047/patient), €15,000 (mEVPI €3,101/patient) and €25,000 (mEVPI €1,564/
patient) per QALY gained, respectively.CONCLUSIONS: First-line R-maintenance is
an efficient and potentially cost-effective start for FL-treatment sequence.
VI4
THE VALUE OF INFORMATION OF A MULTICENTRE RANDOMISED CONTROLLED
TRIAL OF INTRAVENOUS IMMUNOGLOBULIN FOR SEPSIS (SEVERE SEPSIS AND
SEPTIC SHOCK)
Soares MO
University of York, York, UK
OBJECTIVES: Sepsis is a syndrome characterised by a systemic inflammatory re-
sponse to infection. Intravenous immunoglobulin (IVIG) has been proposed as an
adjuvant therapy for sepsis. The need for a high quality randomised controlled trial
(RCT) to evaluate the effectiveness of this treatment has been identified in the
literature. The objectives of the current work were to use value of information
analyses (VOI) to establish whether the costs of carrying out an RCT are outweighed
by the potential benefit of the resulting information. METHODS: A decision model
was developed to evaluate the cost-effectiveness of IVIG (in terms of cost per qual-
ity-adjusted life-year) in adults with severe sepsis. A systematic review coupled
with formal modelling selection process was performed to assess evidence on the
relative effectiveness of IVIG. Further reviews were conducted to inform other
relevant model parameters. Decision uncertainty was presented and the value of
information assessed. RESULTS: A large degree of between study heterogeneity in
the existing evidence base over the relative effectiveness of IVIG could be explained
by a measure of study quality and duration of IVIG therapy. When using this model,
the incremental cost-effectiveness ratio of IVIG was estimated to be £20,850 per
QALY (threshold of £20,000 per QALY), and the probability of IVIG being cost effec-
tive was 0.505. No clear clinical rationale for the association between relative ef-
fectiveness and duration of therapy emerged from existing studies. Alternative
models were evaluated for their impact on cost effectiveness and on the need for
further research. The results demonstrate that conclusions are highly sensitive to
the choice of model used for clinical effectiveness. CONCLUSIONS: Although the
analyses suggested potential value from a large multicentre RCT, the uncertainties
around the design of such a study mean that further dose-ranging/finding studies
should conducted prior to funding any future multicentre RCT.
PODIUM SESSION III:
TAKING HETEROGENEITY INTO ACCOUNT BETWEEN PATIENTS AND BETWEEN
STUDIES
HG1
APPLYING FRAILTY MODEL IN LONGITUDINAL SURVIVALS OF CHRONIC
DISEASES
Li Y, Holtzer-Goor K, Uyl-de Groot C, Al M
iMTA, Erasmus University Rotterdam, Rotterdam, The Netherlands
OBJECTIVES: Survival analysis plays an important role in assessing the effective-
ness of medical product/treatments and the risk factors. Particularly, the acceler-
ated failure time (AFT) model provides the hazard/survival functions to the later
health economic decision model to compute the cost-effectiveness. The model
estimations of the usual survival models rely on the maximum likelihood estima-
tion (MLE), which works under the assumption of independence of observations.
However, this assumption is not always satisfied, especially in the chronic/relaps-
ing disease. A patient with a chronic disease may experience recurrent disease
progressions in the life course. When the progression free survivals (PFS) are re-
corded longitudinally, the PFS of different patients can be considered independent.
Nevertheless, owing to sharing some unobserved heterogeneity, PFS of the same
patients tend to associate with each other. This within-patient association can
affect the estimation accuracy, therefore may misinform the decision makers. Par-
ticularly designed for the multivariate survival analysis, the frailty model takes this
issue into account. METHODS: Fist, in a simulation study, we compared the AFT
model and the Frailty model, where 5000 hypothetical patients are assigned to two
treatment arms, and each patient experiences 5 treatment lines. Second, we apply
both the Weibull AFT model and the Weibull-Gamma frailty model to the real life
data, where 254 patients of chronic lymphocytic leukemia(CLL) have been fol-
lowed, and we conduct a hypothesis test on the significance of frailty term.
RESULTS: The simulation study shows that the estimates of the AFT model deviate
far from the true values when the unobserved heterogeneity is large. The real life
study indicates that the AFT model should be replaced by the frailty model due to
the significance of the frailty term. CONCLUSIONS: In modelling survivals for
chronic disease, the frailty models provide more accurate effect estimation than
the conventional survival model.
HG2
CHARACTERIZING THE INDIVIDUAL COURSE OF HEALTH-RELATED QUALITY
OF LIFE AFTER SUBARACHNOID HEMORRHAGE
Winter Y1, Klotsche J2, Ringel F3, Spottke A4, Gharevi N4, Klockgether T4, Schramm J4,
Urbach H4, Wittchen HU2, Rehm J2, Meyer B3, Dodel R1
1Philipps-University, Marburg, Germany, 2Technical University Dresden, Dresden, Germany,
3Klinikum rechts der Isar, Technical University, Munich, Germany, 4University of Bonn, Bonn,
Germany
OBJECTIVES: Subarachnoid hemorrhage (SAH) is a cerebrovascular disease leading
to severe disability. SAH-patients show heterogeneous profiles of health-related
quality of life (HrQoL). No methodological approaches to characterize the individ-
ual course of HrQoL following SAH have been developed. The objective was to
characterize individual trajectories concerning HrQoL following SAH by using la-
tent growth mixture modeling (LGMM). METHODS: A total of 113 incident patients
with aneurysmal SAH treated in the University of Bonn between January 2004 and
December 2005 were recruited in this longitudinal study. Clinical parameters (Hunt
and Hess scale, Barthel-Index, Rankin Scale, Beck Depression Inventory) and HrQoL
data (EQ-5D) were evaluated at baseline, 6 and 12 months. LGMM was applied to
analyse the heterogeneity in individual courses of HrQoL after SAH. RESULTS: We
identified four subgroups of patients (latent classes) with different patterns of
HrQoL-course. Class 1 had the worst HrQoL-course with a low score of the EQ-5D
index at baseline (0.33) and a non-significant change in scores over time. Patients in
class 3 showed rapid recovery from initially low EQ-5D scores (0.37) during the first
6 months (D0.47). Patients in classes 2 and 4 had 48-57% better initial HrQoL and
similarly high HrQoL scores after 12 months. Patients in class 4 experienced a
temporary reduction of HrQoL by 55%. The following clinical parameters were
identified to characterize differences between classes: severity of SAH (Hunt and
Hess scale), functional outcome, cognitive impairment and post-stroke depression.
Treatment of post-stroke depression in classes 1 and 4 can improve HrQoL mea-
sures by factor 1.3-2.8. CONCLUSIONS: This methodological approach can be ap-
plied for more elaborated understanding of individual differences in long-term
course of HrQoL after SAH. Identification of different patterns of disease course
using LGMM may help to find subgroups of treatment responders and to assist the
development of individual therapy regimes.
HG3
COST COMPARISONS AND METHODOLOGICAL HETEROGENEITY IN COST-OF-
ILLNESS STUDIES: THE EXAMPLE OF COLORECTAL CANCER
Hanly P1, O’Ceilleachair A2, Skally M3, O’Neill C4, Sharp L3
1National Cancer Registry, Cork, Co. Cork, Ireland, 2National Cancer Registry, Cork, Cork,
Ireland, 3National Cancer Registry Ireland, Cork, Cork, Ireland, 4National University of Ireland
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OBJECTIVES: Colorectal cancer (CRC) is the third most commonly-diagnosed can-
cer worldwide with over one million new cases globally each year. Advances in
treatment and survival have been occurring, which is likely to have increased
lifetime costs of managing the disease. We systematically reviewed and critiqued
the cost-of-illness (COI) literature on CRC. METHODS: We searched Medline, EM-
BASE, CRD and the Cochrane library for CRC COI studies published in English,
January 2000- February 2011. Data was abstracted independently by two reviewers
on: setting, patient population, top-down/bottom-up costs, incident/prevalent ap-
proach, payer perspective, time horizon, costs included, cost source and per-per-
son costs. We developed a framework to compare study methodologies and assess
homogeneity/heterogeneity. RESULTS: Twenty-six papers met the inclusion crite-
ria from the US (17), France (3), the UK (2), Canada (2), Switzerland (1) and Taiwan
(1). Extensive methodological heterogeneity existed between studies. 17 studies
employed top-down costings; 6 studies were prevalent, 8 incident and the remain-
der mixed. Time horizons ranged from 1-year post-diagnosis to lifetime. 25 studies
included healthcare payer direct medical costs; 2 included indirect costs; 1 consid-
ered patient costs. The included papers described case-control studies based on
claims/reimbursement data(10), examinations of patient charts (5) and analysis of
claims data(4). There was broad agreement in how studies accounted for time, but
few studies described costs in sufficient detail to allow repeatability. In general
costs were not comparable between studies. There were some commonality in
findings between studies from the same setting and which estimated costs in the
year following diagnosis, but estimates varied greatly for longer time horizons.
CONCLUSIONS: Methodological heterogeneity and lack of transparency made it
almost impossible to compare CRC costs between studies or over time. For COI
studies to be more informative, and amenable to external comparison, researchers,
decision-makers and funders should adopt more standardised methodologies and
promote greater transparency.
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